Ronald Blue Trust Inc. Has $298,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Posted by Defense World Staff on Jun 30th, 2023

Gilead Sciences logo Ronald Blue Trust Inc. boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,465 shares of the biopharmaceutical company’s stock after buying an additional 370 shares during the period. Ronald Blue Trust Inc.’s holdings in Gilead Sciences were worth $298,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of GILD. Altshuler Shaham Ltd lifted its holdings in shares of Gilead Sciences by 7.0% in the fourth quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 121 shares in the last quarter. John G Ullman & Associates Inc. lifted its stake in Gilead Sciences by 3.2% during the 4th quarter. John G Ullman & Associates Inc. now owns 3,974 shares of the biopharmaceutical company’s stock valued at $341,000 after acquiring an additional 124 shares in the last quarter. Jacobs & Co. CA boosted its holdings in Gilead Sciences by 0.5% during the 4th quarter. Jacobs & Co. CA now owns 26,986 shares of the biopharmaceutical company’s stock worth $2,316,000 after acquiring an additional 127 shares during the last quarter. Canandaigua National Corp grew its stake in shares of Gilead Sciences by 1.4% in the 4th quarter. Canandaigua National Corp now owns 9,526 shares of the biopharmaceutical company’s stock worth $818,000 after acquiring an additional 129 shares in the last quarter. Finally, Heritage Wealth Management LLC raised its holdings in shares of Gilead Sciences by 54.6% in the fourth quarter. Heritage Wealth Management LLC now owns 368 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 130 shares during the last quarter. Institutional investors and hedge funds own 81.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GILD. BMO Capital Markets raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $90.00 to $100.00 in a research report on Tuesday, May 16th. Morgan Stanley increased their price target on Gilead Sciences from $81.00 to $85.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 12th. Royal Bank of Canada cut their price objective on Gilead Sciences from $87.00 to $86.00 and set a “sector perform” rating on the stock in a research report on Monday, March 6th. Finally, StockNews.com assumed coverage on Gilead Sciences in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. Eight investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $91.00.

Gilead Sciences Stock Down 0.2 %

GILD stock opened at $76.01 on Friday. The stock has a 50-day simple moving average of $78.83 and a two-hundred day simple moving average of $81.88. Gilead Sciences, Inc. has a twelve month low of $59.27 and a twelve month high of $89.74. The firm has a market capitalization of $94.81 billion, a PE ratio of 17.16, a PEG ratio of 0.88 and a beta of 0.39. The company has a quick ratio of 1.13, a current ratio of 1.28 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD – Free Report) last posted its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.37 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.26). Gilead Sciences had a return on equity of 39.35% and a net margin of 20.65%. The firm had revenue of $6.35 billion for the quarter, compared to the consensus estimate of $6.33 billion. During the same period last year, the company posted $2.12 EPS. The business’s revenue was down 3.6% on a year-over-year basis. On average, equities analysts predict that Gilead Sciences, Inc. will post 6.74 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 29th. Investors of record on Thursday, June 15th were given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 3.95%. The ex-dividend date was Wednesday, June 14th. Gilead Sciences’s payout ratio is 67.72%.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 1,485 shares of the business’s stock in a transaction dated Tuesday, June 13th. The stock was sold at an average price of $76.90, for a total transaction of $114,196.50. Following the completion of the transaction, the insider now owns 29,402 shares of the company’s stock, valued at $2,261,013.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.